<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1057">
  <stage>Registered</stage>
  <submitdate>6/02/2006</submitdate>
  <approvaldate>6/02/2006</approvaldate>
  <nctid>NCT00288236</nctid>
  <trial_identification>
    <studytitle>Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)</studytitle>
    <scientifictitle>A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed-Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/Day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled With Insulin</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EFC5593</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rimonabant (SR141716)
Treatment: drugs - Placebo

Treatment: drugs: Rimonabant (SR141716)


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absolute change in HbA1C from baseline to Week 48</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides, safety (physical examination, vital signs, laboratory tests, adverse events).</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female patients aged greater than or equal to 18 years.

          -  Diagnosis of type 2 diabetes as defined by WHO criteria.

          -  Type 2 diabetes treated with insulin for at least 3 months (insulin dose of at least
             30 U/day for at least 4 weeks).

          -  HbA1C greater than or equal to 7%.

          -  Having signed the informed consent form.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>General:

          -  Weight loss &gt; 5 kg within 3 months prior to screening visit.

          -  Pregnancy or lactation.

          -  Absence of medically approved contraceptive methods for females of childbearing
             potential.

          -  Administration of other investigational drugs within 30 days prior to screening visit.

          -  Previous participation in a Rimonabant study.

          -  Presence or history of allergic reaction or intolerance to multiple drugs.

        Related to endocrine and metabolic disorders:

          -  Presence of any clinically significant endocrine disease according to the
             Investigator.Note: euthyroid patients on replacement therapy will be included if the
             dosage of thyroxine is stable for at least 3 months prior to screening visit.

          -  Fasting C-peptide &lt; 1.0 ng/mL.

        Related to other disorders:

          -  Presence of any severe medical or psychological condition that in the opinion of the
             Investigator would compromise the patient's safety or successful participation in the
             study.

          -  Presence or history of cancer within the past 5 years with the exception of adequately
             treated localized basal cell skin cancer or in situ uterine cervical cancer.

        Related to laboratory findings:

          -  Positive test for hepatitis B surface antigen and/or hepatitis C antibody.

          -  Abnormal TSH level (TSH &gt; ULN or &lt; LLN).

          -  Positive urine pregnancy test.

        Related to previous or concomitant medications:

          -  Antidiabetic drugs other than insulin within 3 months prior to screening visit.

          -  Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>368</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-Aventis - Lane Cove</hospital>
    <postcode> - Lane Cove</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Providencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Gouda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Guildford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary: Effect on HbA1c over 48 weeks in insulin-treated patients with type 2 diabetes

      Secondary: Effect on glucose, total daily insulin dose, body weight, waist circumference,
      HDL-cholesterol, triglycerides - Safety, tolerability</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00288236</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>